Consequently, given the higher thrombotic rate (around 3.7–4%) reported in this population [12, 51, 52, 108, 109], primary prophylactic treatment is recommended among patients with aPL and an associated autoimmune disease [23]. This evidence concerns the gene FASLG and autoimmune disease.